A novel synthetic approach for the Piperazynyl Pyrimidine Intermediate: Focus on the cost cutting of Buspirone drug at commercial level

Background Buspirone is a critical in treatment for generalized anxiety disorder (GAD), but the synthesis of its key intermediate, 2-(piperazin-1-yl)pyrimidine faces challenges in terms of cost, yield and purity. Traditional synthesis methods are hindered by high material costs and significant by-product formation, necessitating a more efficient and economical approach.